Heron Therapeutics received a formal notice from Nasdaq on June 25, 2026, regarding non-compliance with the minimum $1.00 bid price rule. The deficiency is based on the company's closing bid price remaining below $1.00 for 30 consecutive trading days between May 12, 2026, and June 24, 2026. The company has been granted an initial 180-day grace period, expiring December 22, 2026, to regain compliance. Compliance is regained if the stock price closes at or above $1.00 for at least 10 consecutive business days during the grace period. The company's shares continue to trade on The Nasdaq Capital Market under the ticker symbol HRTX without immediate impact.